Evidence map›Paper›PMID 39670314›Full record

ArticleChemMedChem2025

Third-Generation CD73 Inhibitors Based on a 4,6-Disubstituted-2-Thiopyridine Scaffold.

Félix Grosjean, Maria Shaldaeva, Emeline Cros-Perrial, Céline Rodriguez, Rayane Ghoteimi, Aurélien Lebrun, Zhan-Guo Gao, Jean-Pierre Uttaro, Christophe Mathé, Kenneth A Jacobson and 4 more

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Félix GrosjeanInstitut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard, Univ. Montpellier, CNRS, ENSCM, 34293, Montpellier, France.
Maria ShaldaevaInstitut de Recherche en Infectiologie de Montpellier (IRIM), Univ. Montpellier, CNRS, 34293, Montpellier, France.
Emeline Cros-PerrialCancer Research Center of Lyon (CRCL), INSERM 1052 - CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, France.ORCID https://orcid.org/0000-0003-3508-5051
Céline RodriguezCancer Research Center of Lyon (CRCL), INSERM 1052 - CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, France.
Rayane GhoteimiInstitut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard, Univ. Montpellier, CNRS, ENSCM, 34293, Montpellier, France.
Aurélien LebrunInstitut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard, Univ. Montpellier, CNRS, ENSCM, 34293, Montpellier, France.ORCID https://orcid.org/0000-0002-0801-9684
Zhan-Guo GaoLaboratory of Bioorganic Chemistry, National Institutes of Health, Bethesda, MD, 20892-0810, USA.
Jean-Pierre UttaroInstitut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard, Univ. Montpellier, CNRS, ENSCM, 34293, Montpellier, France.
Christophe MathéInstitut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard, Univ. Montpellier, CNRS, ENSCM, 34293, Montpellier, France.ORCID https://orcid.org/0000-0003-3114-9361
Kenneth A JacobsonLaboratory of Bioorganic Chemistry, National Institutes of Health, Bethesda, MD, 20892-0810, USA.ORCID https://orcid.org/0000-0001-8104-1493
Lars Petter JordheimCancer Research Center of Lyon (CRCL), INSERM 1052 - CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, France.ORCID https://orcid.org/0000-0003-3948-7090
Christine Ménétrier-CauxCancer Research Center of Lyon (CRCL), INSERM 1052 - CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69008, Lyon, France.
Laurent ChaloinInstitut de Recherche en Infectiologie de Montpellier (IRIM), Univ. Montpellier, CNRS, 34293, Montpellier, France.
Suzanne PeyrottesInstitut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard, Univ. Montpellier, CNRS, ENSCM, 34293, Montpellier, France.ORCID https://orcid.org/0000-0003-1705-0576

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Drugs that Act at Adenosine ReceptorsZ01DK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$854k
Institut National du Cancer INCa_11560Intramural NIH HHS Z01 DK031117Intramural NIH HHS ZIA DK031117NIDDK NIH HHS ZIADK031117
6 · The paper itself

Abstract

Various series of 4,6-disubstituted-2-thiopyridine derivatives were synthesized and evaluated as potential ecto-5'-nucleotidase (CD73) inhibitors. Altogether, about ninety compounds were prepared using a general synthetic pathway involving one or two steps (eventually one-pot) procedures. Variation of the nature of the substituents in positions 4 and 6 (methyl, trifluoromethyl or phenyl) of the thiopurine ring, as well as on the thiol function, was examined and led to marked differences both in term of reactivity and ability to interfere with the putative target protein. Using a functional assay on immune cells, few compounds belonging to series 4 were shown to be able to antagonize the inhibition of the T-cell proliferation at both 100 μM and 10 μM (completely for 4 ab and partially for 4 ai), that is as potent as AOPCP which entirely reversed the inhibitory impact of exogenous ATP on T cell proliferation until 62.5 μM. In addition, we have shown that both compounds (4 ab and 4 ai) were also capable of moderately inhibiting the hA

Indexed as

5'-NucleotidaseEnzyme InhibitorsPyridinesCell ProliferationDose-Response Relationship, DrugGPI-Linked ProteinsHEK293 CellsHumansMolecular StructureStructure-Activity RelationshipT-Lymphocytes5'-NucleotidaseEnzyme InhibitorsGPI-Linked ProteinsNT5E protein, humanPyridines5’-ectonucleotidaseAdenosine receptorsEnzyme inhibitorMedicinal chemistryNitrogen heterocyclesThiopyridine

Identifiers

PMID39670314
PMCPMC12421438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.